10.16USD-1.84%Mkt Cap: 269.37M USDP/E: —Last update: 2026-05-26
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NX…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap269.37M USD
Enterprise Value265.06M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.44M USD
Revenue/Share—
Last Price10.16 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.40
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B20.41
EPS (TTM)-1.31
EPS (Forward)-0.96
52W Range
5.55059% of range13.34
52W High13.34 USD
52W Low5.550 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-143.61%
ROA-83.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.01M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-3.40%
Net Debt-25.13M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio2.27
Quick Ratio2.25
Book Value/Sh0.5360 USD
Cash/Share0.9470 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)16.80 USD
Target Range10.00 USD – 20.00 USD
# Analysts5
Ownership
Shares Out.26.53M
Float15.47M
Insiders41.61%
Institutions18.23%
Short Interest
Short Ratio28.3d
Short % Float8.75%
Short % Out.5.29%
Shares Short1.46M
Short (prev mo.)1.58M
Technical
SMA 508.999 (+12.9%)
SMA 2007.611 (+33.5%)
Beta-0.12
S&P 52W Chg28.31%
Avg Vol (30d)94.40K
Avg Vol (10d)137.98K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—